Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ALX Oncology HoldingsALXO +1.77%31 EBIT per Share is $-1.12 as of Jun. 2026. GuruFocus rates ALXO with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,172 Biotechnology companies, ALX Oncology Holdings ranks better than 50.43% on this metric.
ALX Oncology Holdings's EBIT per Share for the
three
months ended in Jun. 2026 was $-0.13.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.12.
During the past 3 years, the average EBIT per Share Growth Rate was 15.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 0.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for ALX Oncology Holdings's EBIT per Share or its related term are showing as below:
ALXO'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -53 Med: -18.8 Max: 15.7
Current: 15.7
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of ALX Oncology Holdings was 15.70% per year. The lowest was -53.00% per year. And the median was -18.80% per year.
ALXO's 3-Year EBIT Growth Rate is ranked better than 50.43% of 1172
companies
in the Biotechnology industry
Industry Median: 15.35
vs ALXO: 15.70
ALX Oncology Holdings (NAS:ALXO) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
ALX Oncology Holdings EBIT per Share Related Terms
ALX Oncology Holdings EBIT per Share Historical Data
* Premium members only.
The historical data trend for ALX Oncology Holdings's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.12
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALX Oncology Holdings (ALXO) has a EBIT per Share of $-1.12 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on ALX Oncology Holdings and its competitors. According to the industry distribution chart, ALX Oncology Holdings ranks #581 out of 1172 companies in the Biotechnology industry, placing it in the top 49.6%.
Is ALX Oncology Holdings' EBIT per Share too high?
ALX Oncology Holdings' current EBIT per Share is $-1.12. Based on the distribution chart, ALX Oncology Holdings ranks #581 out of 1172 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ALX Oncology Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does ALX Oncology Holdings' EBIT per Share compare to CYDY and BCYC?
According to the Biotechnology industry distribution chart, ALX Oncology Holdings ranks #581 out of 1172 companies for EBIT per Share. This puts ALX Oncology Holdings in the upper half of its industry. The industry median EBIT per Share is 15.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.35, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on ALX Oncology Holdings and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ALX Oncology Holdings's current EBIT per Share is $-1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ALX Oncology Holdings stock overvalued right now?
ALX Oncology Holdings (ALXO) has a current EBIT per Share of $-1.12. The current EBIT per Share is $-1.12. ALX Oncology Holdings' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For ALX Oncology Holdings (ALXO), the current EBIT per Share is $-1.12 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
31GF Score
Get the complete analysis for ALXO
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALXO has been successfully added to your 
